Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 1;131(5):e145186.
doi: 10.1172/JCI145186.

Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms

Javid Moslehi  1 , Andrew H Lichtman  2 , Arlene H Sharpe  3   4 , Lorenzo Galluzzi  5   6   7 , Richard N Kitsis  8
Affiliations
Review

Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms

Javid Moslehi et al. J Clin Invest. .

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: JM has served on scientific advisory boards for Bristol Myers Squibb, Takeda, Deciphera, AstraZeneca, Nektar, Audentes Therapeutics, TripleGene, Boston Biomedical, ImmunoCore, Janssen, Myovant, Cytokinetics, and Amgen. AHS is on the scientific advisory boards for Surface Oncology, SQZ Biotech, Elstar Therapeutics, Elpiscience, Selecta, and Monopteros, consults for Novartis, and has research funding from Merck, Novartis, Roche, Ipsen, and Quark Ventures. AHS has patents/pending royalties from Roche and Novartis on intellectual property on the PD-1 pathway (patent 7,432,059 with royalties paid from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; patent 7,722,868 with royalties paid from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; patents 8,652,465 and 9,457,080 licensed to Roche; patents 9,683,048, 9,815,898, 9,845,356, 10,202,454. and 10,457,733 licensed to Novartis; and patents 9,580,684, 9,988,452, and 10,370,446 issued to none). LG has received research funding from Lytix and Phosplatin, as well as consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. RNK is cofounder and president of ASPIDA Therapeutics Inc. RNK has a patent (PCT/ US2018/021644) for small-molecule BAX inhibitors.

Figures

Figure 1
Figure 1. Immune checkpoints in T cell priming and activation.
(A) Mature, but naive, T cells are primed in secondary lymphoid organs. The priming process requires engagement of the TCR by its specific antigenic ligand, which consists of antigen-derived peptides displayed on the surface of antigen-presenting cells (APCs) in the context of MHC molecules; and costimulatory signals provided, in part, by binding of CD80/86 on the surface of APCs to CD28, which is constitutively present on T cells. Full effector functions are acquired in peripheral tissues when the TCR re-encounters its specific antigenic ligand. Priming and later activation steps also result in induction of CTLA-4 and PD-1, respectively, which are coinhibitory receptors that are expressed on the surface of T cells and function as immune checkpoints. (B) CTLA-4 outcompetes CD28 for binding to CD80/86, thereby attenuating CD28-mediated costimulation, reflecting the stronger affinity of CD80/86 for CTLA-4 as compared with CD28 and the upregulation of CTLA-4 during priming. Following binding by its ligands, PD-L1 and PD-L2 (not shown), PD-1 suppresses T cell activation through cell-intrinsic mechanisms that disrupt signaling downstream of TCR (see main text). Genetic alterations or interferon stimulation in cancer cells can induce PD-L1, providing a mechanism for these cells to evade killing by the immune system. IFN-γ–induced expression of PD-L1 on cardiac endothelial cells also provides a means for the heart to protect itself against T cells. Not shown is the role of Tregs (see main text). (C) Approved ICIs are monoclonal antibodies that bind CTLA-4, PD-1, or PD-L1, thereby disrupting interactions between CD80/86 and CTLA-4 and between PD-1 and PD-L1, respectively.
Figure 2
Figure 2. Example of ICI-associated myocarditis.
A 65-year-old woman with metastatic melanoma treated with ipilimumab (3 mg/kg i.v.) and nivolumab (3 mg/kg i.v.) developed atypical chest pain, dyspnea, and fatigue 12 days later, accompanied by (A) ECG showing sinus rhythm with first-degree atrioventricular block, which progressed to complete heart block. (B) Several hours later, ECG showed ventricular tachycardia, which degenerated to ventricular fibrillation and cardiac arrest. The patient could not be resuscitated. (C) At autopsy, cardiac tissue stained with hematoxylin and eosin showed myocyte degeneration accompanied by a mononuclear cell infiltrate, immunostaining of which showed prominence of CD68, a macrophage marker (not shown). (D) Also seen was marked infiltration of T cells, as shown by immunostaining for CD3. This infiltrate included approximately equal proportions of CD4+ and CD8+ T cells (not shown). In addition, immunostaining for CD20, a B cell marker, and IgG was not detected (not shown). Scale bar: 0.1 mm. aVR, augmented vector right; aVL, augmented vector left; aVF, augmented vector foot. Reproduced with permission from the New England Journal of Medicine (13).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060. - DOI - PMC - PubMed
    1. Galluzzi L, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. doi: 10.1038/s41571-020-0413-z. - DOI - PubMed
    1. Wei SC, et al. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi: 10.1158/2159-8290.CD-18-0367. - DOI - PubMed
    1. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75–76. doi: 10.1038/s41577-020-0275-8. - DOI - PubMed
    1. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39. doi: 10.1038/s41577-019-0218-4. - DOI - PMC - PubMed

Publication types

MeSH terms